September 17, 2020
Stephen Miller has been appointed Chief Commercial Officer, of Biofidelity based in the US. Following Biofidelity’s recent $12m Series A financing, supported by experienced investors BlueYard Capital, Longwall Ventures and Agilent Technologies, the Company is now focused on expanding its executive team, a critical step in its commercial strategy. The appointment of Stephen Miller follows former Roche executive, Heiner Dreismann, joining the Board as Chairman.
Stephen Miller joins Biofidelity with more than 25 years of experience in the leadership of high growth diagnostics businesses in the US. He has held significant leadership positions at both public and private companies, including, Precipio Inc., BG Medicine, Thermo Fisher Scientific, and Athena Diagnostics. Athena Diagnostics was purchased by Thermo Fisher Scientific for $283m under his commercial leadership and Athena was later purchased by Quest Diagnostics from Thermo Fisher for $740m.
Dr. Barnaby Balmforth, Chief Executive Officer of Biofidelity, commented: “Biofidelity is at an exciting juncture as we ready our oncology diagnostic platform for launch. We are focused on building the right team of high caliber and renowned industry experts and we are delighted to welcome Stephen to the Company. His diagnostics expertise, commercial experience, and industry network will be crucial in the execution of our commercial strategy, particularly in the critical US market. Only a fraction of patients currently have access to the best oncology diagnostics and we believe that our unique diagnostics platform has the potential to revolutionize this access and enable oncologists to provide all patients with the right treatment at the right time.”
Stephen Miller added: “What attracted me to Biofidelity is the novel diagnostic platform, which I believe has the potential to change the dynamics of cancer diagnosis and treatment. Many oncologists struggle with access to clinically actionable test results. With the Biofidelity platform, laboratories will be able to test for these clinically actionable mutations and provide the results to oncologists in a fraction of the time and ata lower cost compared to current testing technologies.I look forward to working with Barney, Heinerand the rest of the Biofidelity team.”
